Abstract
No public abstract is available from the verified source records.
Stephen M Humphries, James L Crooks, Joseph B Pryor
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Rheumatoid arthritis–interstitial lung disease in the United States: prevalence, incidence, and healthcare costs and mortality
10.3899/jrheum.171315 · 2019
Rheumatoid arthritis-interstitial lung disease-associated mortality
10.1164/rccm.201004-0622oc · 2011
ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease
10.1183/13993003.02533-2024 · 2026
2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases
10.1002/acr.25347 · 2024
Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease
10.1093/rheumatology/kes289 · 2013
Idiopathic pulmonary fibrosis: data-driven textural analysis of extent of fibrosis at baseline and 15-month follow-up
10.1148/radiol.2017161177 · 2017
Deep learning–based fibrosis extent on computed tomography predicts outcome of fibrosing interstitial lung disease independent of visually assessed computed tomography pattern
10.1513/annalsats.202301-084oc · 2024
Quantitative CT scan analysis in rheumatoid arthritis-related interstitial lung disease
10.1016/j.chest.2024.10.052 · 2025
Prospective identification of subclinical interstitial lung disease in a rheumatoid arthritis cohort is associated with the MUC5B promoter variant
10.1164/rccm.202109-2087le · 2022
Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study
10.1016/s2213-2600(22)00260-0 · 2023
No additional external references are available.